
ARS Pharmaceuticals (NASDAQ:SPRY) reported first-quarter 2026 revenue of $22.7 million as executives said the company is working to expand access, reduce prescribing friction and build momentum for neffy, its needle-free epinephrine treatment for allergic reactions including anaphylaxis.
Co-founder, President and Chief Executive Officer Richard Lowenthal said the company generated $17.5 million in U.S. net product revenue for neffy during the quarter, with prescription volume tripling year over year and revenue more than doubling. He characterized the quarter as a “strong start” to 2026, particularly because the first two months of the year are typically the lowest-volume period for epinephrine products due to the reset of health insurance deductibles.